Biolojic Design is a biopharmaceutical company dedicated to the development of human antibody-based therapeutics for cancer and other diseases. Biolojic Design has developed a new tool to re-engineer antibodies to bind new epitopes in a process known as re-epitoping. This technology has been shown to yield functional antibodies in difficult targets. Using proprietary algorithms, the company identifies an existing antibody that can be re-epitoped to bind the desired target. The antibody template is then engineered in an iterative computational and experimental approach to bind the desired epitope with high affinity. In 2014, Biolojic partnered with AstraZeneca's MedImmune LLC Biologics unit to discover antibodies for undisclosed targets selected by MedImmune, using Biolojic's computational and biochemical tools.